In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents on the choline and sodium salt of the drug lenacapavir. The Indian ...

Baylen, Paige Cowett, Rowan Niemisto, Dan Powell, Elisheba Ittoop, Marion Lozano and Alyssa Moxley Gilead delayed a new version of a drug, allowing it to extend the patent life of a ...

We'll use ROE to examine Gilead Sciences, Inc. (NASDAQ:GILD), by way of a worked example. Return on equity or ROE is a key measure used to assess how efficiently a company's management is ...

Chris Schott has given his Buy rating due to a combination of factors revolving around Gilead Sciences’ drug, lenacapavir, and its potential impact on the market. Schott points out the ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...

“Daina Graybosch has given his Hold rating due to a combination of factors surrounding Gilead Sciences’ prospects with its new drug, lenacapavir.” Daina Graybosch’s assessment of Gilead ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Almost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – and now the UK pharma is reportedly planning its own mega-merger with Gilead.